Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cannabis-Using MS Patients Improve Cognition With 28 Days of Abstinence

Publish date:: October 15, 2019

Key clinical point: Multiple sclerosis (MS) patients who are heavy users of cannabis gain significantly improved cognitive function with a month of abstinence – but do they care?

Major finding: Twenty-eight days of abstinence from cannabis by MS patients who were heavy users resulted in significant improvements in cognition.

Study details: This was a randomized trial involving 40 MS patients who were long-term frequent users of cannabis for symptom relief.

Disclosures: Cecilia Meza, who presented the results, reported having no financial conflicts regarding the study, funded by the Multiple Sclerosis Society of Canada.

Citation:

Meza C. ECTRIMS 2019, Abstract P542.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Neurology

HIT-6 may help track meaningful change in chronic migraine,

Vascular dementia risk particularly high in type 2 diabetes,

Low VWF levels or blood group O not linked to intracerebral hemorrhage risk,

Blood biomarkers could help predict when athletes recover from concussions,

Mortality burden of dementia may be greater than estimated,